BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...disease and amyotrophic lateral sclerosis. ANX005 is a mAb against C1q; and ANX007 is a C1q-binding...
...PXE) - ATP-binding cassette sub-family C member 6 Btk - Bruton’s tyrosine kinase C1q - Complement component 1 q subcomponent...
...Inc. Inozyme Pharma Inc. ADiTx Therapeutics Inc. Immatics Biotechnologies GmbH Arya Sciences Acquisition Corp. Perceptive Advisors RA Capital Management Deerfield Management Co. L.P. Complement component 1 q subcomponent (C1q) IPO...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
BioCentury | May 1, 2020
Distillery Therapeutics

Complement component C1q as a hepatitis-associated liver cancer target

...cancer Inhibiting the complement component C1q could treat hepatocellular carcinoma (HCC) associated with chronic hepatitis. C1q...
...in normal liver tissue hemangioma patients. In mice genetically predisposed to developing liver tumors, two C1q...
...suppressed proliferation of hepatic progenitor cells, a cell type from which HCC can originate. TARGET/MARKER/PATHWAY: Complement component 1 q subcomponent (C1q)...
BioCentury | Apr 22, 2020
Finance

April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

...Norfolk, Va.-based company plans to begin clinical testing of RLS-0071, a peptide engineered to inhibit C1q...
...diseases. Targets C1q - Complement component 1 q subcomponent MBL2 (MBL) - Mannan-binding lectin BioCentury Staff New Horizon Health Technology Co. Ltd. Complement component 1 q subcomponent (C1q) Cloudbreak...
BioCentury | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

Having met the primary endpoint in the pivotal CARDINAL trial, Sanofi’s sutimlimab could become the first approved therapy for primary cold agglutinin disease. According to the company, the data are the first Phase III results...
BioCentury | Sep 19, 2019
Targets & Mechanisms

Regeneron's new take on bispecifics: activating complement

...initiate the classical complement cascade at a target cell, which starts with the accumulation of C1q...
...C1q, allowing it to recruit other C1q molecules and trigger the cascade. In the study, C1q-targeted...
...mechanically ventilated patients. Regeneron has not disclosed development timelines for the platform. Targets: C1q - Complement component 1 q subcomponent...
BioCentury | Jun 5, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

...treat diabetic nephropathy and renal failure Tohoku University Distillery Therapeutics Biomarkers Neurology Alzheimer's disease Complement C1q...
BioCentury | May 7, 2019
Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

...leucine rich repeat and Ig domain containing 1 (LINGO1) in excitatory neurons and oligodendrocytes, complement C1q...
...email: lhtsai@mit.edu Sandi Wong Broad Institute of MIT and Harvard Massachusetts Institute of Technology Adenosine deaminase RNA-specific B2 (ADARB2) Complement C1q...
BioCentury | May 1, 2019
Translation in Brief

White matter matters in Alzheimer’s

...and neurodegenerative diseases (see "A Venture View of Biological White Space" ). Targets: C1QB - Complement component 1 q subcomponent...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...AL003 AD Ph I Complement Complement 6 (C6) Complement Pharma CP 010 Wallerian degeneration Preclin Complement component 1 q subcomponent (C1q)...
...aging, C1q accumulates on synapses, but doesn’t activate,” Yednock said, adding that it’s unknown what C1q...
...South San Francisco, Calif. Inflazome Ltd., Dublin, Ireland Stanford University, Stanford, Calif. Targets C1q - Complement component 1 q subcomponent...
Items per page:
1 - 10 of 54